# Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature

## TL;DR

Tocilizumab, an anti-inflammatory drug, may help treat a severe blood disorder in sickle cell disease patients, as shown in four case studies.

## Contribution

This paper presents four new clinical cases where tocilizumab effectively treated hyperhaemolysis syndrome in sickle cell disease.

## Key findings

- All four patients showed rapid improvement in hemolysis after receiving tocilizumab.
- Two patients received blood transfusions without recurrence of hemolysis.
- Tocilizumab is suggested as a cost-effective and widely available treatment option.

## Abstract

Hyperhaemolysis syndrome is a life‐threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti‐IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases. In this paper, we review four cases of hyperhaemolysis treated with tocilizumab in the context of the existing literature.

Cases of use of tocilizumab in hyperhaemolysis were identified from two large specialist haemoglobinopathy centres between the period January 2021 and March 2025. Clinical and laboratory data were collected.

Four cases of hyperhaemolysis treated with IVIG, steroids and tocilizumab were reported. In all cases, haemolysis responded rapidly to tocilizumab therapy. Two patients subsequently received RBC transfusions without haemolysis; two patients died from causes unrelated to haemolysis.

This case series supports the use of tocilizumab as a therapeutic option for rapid resolution of haemolysis. It is generally widely available and should be considered a suitable and cost‐effective alternative to currently available options.